Shalini Gupta, MD
Dermatology · Cincinnati, OHNPI 1245437680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,500 of the $4,197 with a category attached, or 83.4%. AbbVie accounts for 85.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $3,500 and has fallen 96.8% since, to $110 in 2025.
Across 30 payments — averaging $139.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$124
- Merz North America, Inc.$103
- UCB, Inc.$74
- Lilly USA, LLC$70
- Verrica Pharmaceuticals Inc.$45
- plus $191 from 9 others
What the payments were for
- Speaking & faculty fees$3,50083%
- Food & beverage$69717%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 5 | $3,589 |
| AstraZeneca | 1 | $124 |
| Merz North America, Inc. | 4 | $103 |
| UCB, Inc. | 4 | $74 |
| Lilly USA, LLC | 3 | $70 |
| Verrica Pharmaceuticals Inc. | 2 | $45 |
| Nobelpharma America, LLC | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 2 | $28 |
| Organogenesis Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Novartis | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Amgen | 1 | $14 |
| Acelrx Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$124
How this compares
$4,197 in reported general payments places this provider in the 60th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Triamcinolone Acetonide | 12 | $297 |
| Ketoconazole | 13 | $244 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Cincinnati
- Mona FoadCincinnati$212K
- Alan FleischerCincinnati$34K
- Matthew ZirwasBexley$3.3M
- George DrewMarion$1.9M
- Rocco SerraoDayton$1.7M
- James LibeccoFairlawn$1.1M
- Pranav ShethWest Chester$978K
- Dawn MerrittAthens$844K
- Neil KormanCleveland$824K
- Joshua GrosshandlerWesterville$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.